- |||||||||| UCB8600 / UCB
Trial completion date, Trial termination, Trial primary completion date: A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UCB8600 in Healthy Participants, Atopic Participants, and Chronic Spontaneous Urticaria Participants (clinicaltrials.gov) - Sep 9, 2021
P1, N=40, Terminated,
Trial completion date: Jul 2022 --> Aug 2021 | Active, not recruiting --> Terminated | Trial primary completion date: Jul 2022 --> Aug 2021; internal company decision; not safety related
- |||||||||| UCB8600 / UCB
Enrollment closed, Enrollment change: A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UCB8600 in Healthy Participants, Atopic Participants, and Chronic Spontaneous Urticaria Participants (clinicaltrials.gov) - Aug 5, 2021
P1, N=40, Active, not recruiting,
Trial completion date: Jul 2022 --> Aug 2021 | Active, not recruiting --> Terminated | Trial primary completion date: Jul 2022 --> Aug 2021; internal company decision; not safety related Recruiting --> Active, not recruiting | N=174 --> 40
- |||||||||| UCB8600 / UCB
Trial completion date, Trial primary completion date: A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UCB8600 in Healthy Participants, Atopic Participants, and Chronic Spontaneous Urticaria Participants (clinicaltrials.gov) - Jul 22, 2021
P1, N=174, Recruiting,
Recruiting --> Active, not recruiting | N=174 --> 40 Trial completion date: Aug 2021 --> Jul 2022 | Trial primary completion date: Aug 2021 --> Jul 2022
|
